G1 Therapeutics, Inc. (GTHX) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights
August 3, 2022 6:30 AM EDT- Achieved $8.7 Million in Net Revenue from Sales of COSELA® (trilaciclib) in the Second Quarter of 2022 and $10.6 Million in Total Revenue -
- Completed Patient Enrollment in Pivotal Phase 3 Trial of Trilaciclib in Metastatic Colorectal Cancer (mCRC) (PRESERVE 1) -
- Completed Patient Enrollment in Phase 2 Mechanism of Action Trial of Trilaciclib in Neoadjuvant Triple Negative Breast Cancer (TNBC) -
- Achieved Target Enrollment in Phase 2Â Trial of Trilaciclib in Bladder Cancer (mUC) (PRESERVE 3) -
- Announced Approval of COSELA (trilaciclib hydrochloride for... More
